<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Because endothelin-1 has a potent and long-lasting vasoconstrictive action, it has been proposed that it plays some important roles in the pathogenesis of delayed <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the preventive effect of a novel <z:chebi fb="209" ids="16000,53460">ETA</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, BQ-485, on experimental vasospasm using canine two-<z:mp ids='MP_0001914'>hemorrhage</z:mp> model of <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The IC50 value of BQ-485 on [125I]endothelin-1 binding was 3.4 x 10(-9) M for <z:chebi fb="209" ids="16000,53460">ETA</z:chebi> receptor and 26 x 10(-6) M for ETB receptor </plain></SENT>
<SENT sid="3" pm="."><plain>Systemic continuous administration of 120 mg/day of the agent inhibited the narrowing of canine basilar artery on day 7 following experimental <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (75.0% vs 59.9% (control), p &lt; 0.01) </plain></SENT>
<SENT sid="4" pm="."><plain>The present results suggest that endothelin-1 and <z:chebi fb="209" ids="16000,53460">ETA</z:chebi> receptor participate in the pathogenesis of delayed <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
</text></document>